Press Releases

TranScrip congratulate Orexo AB on gaining US approval for Zubsolv

12th August 2015: TranScrip congratulate Orexo AB on gaining US approval for Zubsolv as induction therapy for opiate dependence, a very difficult treatment phase to address, clinically, and one which many physicians admit is a barrier to them helping patients with addiction. Zubsolv gives them additional options in helping patients who would otherwise continue to struggle with dependency. 

For further detail, please see the press release below.

U.S. FDA Approves ZUBSOLV® for Induction of Buprenorphine Maintenance Therapy in Patients Suffering from Opioid Dependence